

PROMETIC LIFE SCIENCES INC.



PROMETIC

RENEWAL ANNUAL INFORMATION FORM

Year ended December 31, 2002

MAY 18, 2003

TABLE OF CONTENTS

	Forward Looking Statements.....	3
Item 1 -	Corporate Structure	3
1.1	Name and Incorporation	3
1.2	Intercorporate Relationships	4
Item 2 -	General Development of the Business.....	4
2.1	Three-Year History.....	4
2.2	Significant Acquisitions and Significant Dispositions	6
2.3	Trends	6
Item 3 -	Narrative Description of the Business	7
	Core Technologies.....	8
-	Mimetic Ligand™ and “Intelligent Combinatorial Chemistry (ICC)®”	8
-	Particles Technology	8
	Commercial Applications	8
	Competitive Conditions	9
	Availability and Sources of Raw Materials	9
	Intellectual Property Rights	9
	Reliance on Collaborative Partners.....	10
	Product Development	11
	Research and Development	11
	Environment.....	11
	Human Resources	11
	International Business.....	12
Item 4 -	Selected Consolidated Financial Information	12
4.1	Annual information	12
4.2	Dividends.....	12
Item 5 -	Management’s Discussion and Analysis of Financial Position and Operating Results	13
Item 6 -	Market for Securities	13
Item 7 -	Directors and Officers	13
	Directors.....	13
	Officers	14
	Security Holdings	15
Item 8 -	Additional Information	15

Forward Looking Statements

This Annual Information Form contains forward-looking statements about ProMetic's objectives, strategies, financial condition, results of operations and businesses.

These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions.

These statements could be materially different from what we expect if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. As a result, we cannot guarantee that any forward-looking statement will materialize; forward-looking statements do not take into account the effect that transactions or non-recurring items announced or occurring after the statements are made may have on our business; we assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason. You will find a more detailed assessment of the risks that could cause our actual statements to materially differ from our current expectations on p. 16 of the Corporation's 2002 Annual Report under the heading "Risks".

Item 1 – Corporate Structure


1.1 Name and Incorporation

ProMetic Life Sciences Inc. (the "Corporation") was incorporated on October 14, 1994 under the *Canada Business Corporations Act*, originally as Innovon Life Sciences Holdings Limited.

Since October 14, 1994, the Corporation has amended its articles of incorporation by articles of amendment. On December 21, 1995, the Corporation amended its authorized share capital and removed the restrictions on share transfers. It also amended the provisions in its articles pertaining to the Corporation's borrowing powers and those in respect of quorums at board of directors meetings. On June 6, 1996, the Corporation amended the provisions pertaining to the minimum and maximum number of directors. On April 10, 1995, October 10, 1995, June 19, 1997 and August 14, 1997, the Corporation again amended its authorized share capital. On May 19, 1998, the Corporation changed its name from Innovon Life Sciences Holdings Limited to ProMetic Life Sciences Inc. and simplified its authorized share capital structure. Hence, according to restated articles of incorporation dated May 19, 1998, the Corporation is authorized to issue an unlimited number of Subordinate Voting Shares, twenty million (20,000,000) Multiple Voting Shares and an unlimited number of preferred shares issuable in series. By certificate of amendment issued on February 16, 2000, the Corporation created its initial two series of preferred shares consisting of a maximum of one million fifty thousand (1,050,000) Series A Preferred shares and nine hundred fifty thousand (950,000) Series B Preferred shares.

1.2 Intercorporate relationships

The following chart indicates the jurisdiction of incorporation of the Corporation's direct and indirect operating subsidiaries, as well as the voting interest (expressed as a percentage) held or controlled by the Corporation in each subsidiary.



(1) The Corporation is also the shareholder of Pathogen Removal and Diagnostic Technologies Inc., a joint venture company with the American National Red Cross (see page 8 of the Corporation's 2002 Annual Report).

(2) Formerly known as Affinity Chromatography Limited.

(3) The remaining 50% is held by Arriva Pharmaceuticals, Inc. (formerly AlphaOne Pharmaceuticals, Inc.), the Corporation's joint venture partner in the development and marketing of serine protease inhibitors such as AAT (see p. 9 of the Corporation's 2002 Annual Report).

Item 2 – General Development of the Business

The Corporation is a publicly listed biopharmaceutical company (Toronto Stock Exchange: PLI) based in Montreal. Through its subsidiaries ProMetic BioSciences Ltd. and ProMetic BioSciences Inc., (hereinafter collectively with the Corporation referred to as "ProMetic"), ProMetic is engaged in the development, manufacture and commercialization of products for the biopharmaceutical industry. ProMetic's proprietary technology is key to the development and manufacture of proteins. It has commercial applications in a wide range of areas, from proteomics to industrial biopharmaceutical manufacturing, and from blood product safety to diagnostics and therapeutics. ProMetic further leverages its core technologies and competencies by developing proprietary, value-added therapeutics and medical devices.

2.1 Three-Year History

In February 2003, a second strategic alliance agreement between ProMetic and The American National Red Cross (the "ARC") was reached; this new alliance is in respect with an improved process to recover a wide range of life saving medicines from plasma.

Successful equity financing, raising \$ 38.1 Million, was made by the Corporation during the year ending December 31, 2002 out of which \$26.2 Million was obtained via a public offering on June 17, 2002.

Since December 2002, ProMetic's Perfluorosorb™ beads has played an integral part in the manufacture of the DNA-based West Nile virus vaccines developed by the Centre for Disease Control and Prevention (United States).

In November 2002, approval was received from the FDA and Health Canada to move recombinant Alpha 1-antitrypsin into clinical trials for patients suffering from atopic dermatitis.

In November 2002, ProMetic completed GMP synthesis and oral formulation work, preparing PBI-1402 for clinical trials.

In October 2002, ProMetic completed final steps in the commercialization of Perfluorosorb™ beads for use in DNA purification.

In September 2002, ProMetic achieved a milestone in the development of a purification process for Alkaline Phosphatase, a therapeutic drug candidate for the treatment of sepsis and septic shock, with initiation of Phase I clinical study by AM-Pharma Holding B.V.

In June 2002, ProMetic achieved scaleable purification process for Amediplase, Menarini Biotech's ("Menarini") new thrombolytic agent for the treatment of acute myocardial infarction currently in Phase III clinical trials.

In April 2002, ProMetic and ARC, established a joint venture company, "Pathogen Removal and Diagnostic Technologies Inc.", to develop and commercialize detection and removal systems for the elimination of prions, viruses and other pathogens from the human blood supply, blood-derived products and other biopharmaceutical products.

In March 2002, ProMetic developed a powerful platform for the purification of monoclonal antibodies (MAbs) that can apply to most types of MAbs produced by different techniques achieving the required yield and purity while improving process economics.

Successful financing of \$19 Million (gross proceeds) out of which \$9.9 Million was concluded as of December 31, 2001.

In December 2001, ProMetic's research and development team was expanded; the expansion was part of ProMetic's progression of its core technologies into high value therapeutics. Among the appointments announced was Dr. Christopher Penney as Director of R&D, Therapeutic Program.

In December 2001, Merck & Co. initiated its first U.S. Pivotal Clinical Trial for vaccines product using Recombumim? (i.e. Delta's recombinant albumin) for which ProMetic's Mimetic Ligand? Technology is used and scaled up.

In November 2001, an International patent filing for PBI-1101 was made and completion of supportive data for International patent filing for PBI-1402 was finalized.

In October 2001, ProMetic signed a license agreement with PharmAAware Sepsis B.V. for the use of ProMetic's technology in connection with diagnosis and treatment of sepsis and septic shock.

In July 2001, ProMetic announced that Fresenius AG exercised an option to gain additional rights to market recombinant human serum albumin (rHSA) relying on ProMetic's Mimetic Ligand? Technology in North America and in Asia, except Japan.

In April 2001, a strategic alliance was signed with Merck KgaA ("Merck"). The aim of this strategic alliance is to jointly market ProMetic and Merck's capabilities (ProMetic's Mimetic Ligand? Technology) in the purification of monoclonal antibodies (MAbs).

In March 2001, ProMetic entered into a collaboration agreement with Menarini for the use of ProMetic's Mimetic Ligand? Technology in connection with one of Menarini's biopharmaceuticals in phase III.

In December 2000, Delta Biotechnology Ltd. ("Delta", an Aventis Behring Corporation) announced the successful results of its large clinical trials for Recombumin? 20% for which ProMetic's purification technology is used and scaled up.

In December 2000, another collaborative agreement was signed between ProMetic BioSciences Ltd. and Delta to develop a purification process for an yeast derived recombinant human serum albumin (Recombumin?).

In November 2000, ProMetic was granted US Patent 6,117,996, which further consolidated the proprietary position of its enabling platform technology.

In October 2000, ProMetic secured once again its position as a supplier of its advanced technology to the plasma fractionation industry through the signature of a collaborative agreement with Aventis Behring L.L.C. ("Aventis") for the development of a purification process for Aventis.

In May 2000, ProMetic in-licensed of certain patent rights from Convatec (Bristol-Myers Squibb), enabling partnership in the development of improved biomedical devices applied to the treatment and diagnosis of cancer.

In January 2000, ProMetic signed a ten-year supply agreement with Provalis Diagnostics Ltd. for the supply of an essential component for the manufacture of Glycosal™, an innovative diagnostic test kit for diabetes.

2.2 Significant Acquisitions and Significant Dispositions

None

2.3 Trends

The partnership and joint venture agreements concluded over the past few years have enabled ProMetic to position itself as a key player in the biopharmaceutical purification market. This strategy aims at maximizing the Corporation's value and mitigates inherent development risks. Although the financial impact of these alliances on the Corporation's bottom line is not immediate, it provides a significant endorsement of ProMetic's bioseparation technology and enhances its visibility at the international level.

The initiation of a Phase 1b clinical trial of recombinant Alpha 1-antitrypsin (rAAT) through the Arriva-ProMetic Inc. joint venture confirmed the significant progress made by ProMetic's therapeutic division, since research and development (R&D) program spending was accelerated two years ago, rAAT is the first drug compound of its product development pipeline to advance to clinical trials.

Owing to additional discoveries made regarding the activity of its lead compound regarding the activity of its lead compound PBI-1402, ProMetic decided to revise its original clinical development plan, thereby incurring delays. The discoveries led to the filing of new patents and PBI-1402 should enter clinical trials during the third quarter of 2003.

ProMetic's objectives for the coming year include partnering with pharmaceutical and biopharmaceutical companies to improve the manufacturing of their own therapeutics. ProMetic's business model is to accumulate multiple long-term annuity revenues through collaboration based on its core technology, while advancing its own therapeutic products toward commercialization.

Item 3 - Narrative Description of the Business

There are hundreds of protein-derived and DNA based drugs in development, forming the next wave of new therapies and referred to as "biopharmaceuticals". These products are derived from a biological source and each of them poses manufacturing challenges, as the separation and purification of the targeted therapeutic proteins from their biological source a process called "bioseparation", is key to their commercial viability.

ProMetic's core technology is based on unique and proprietary synthetic organic entities called Mimetic Ligands™, key to such activity. These compounds can be compared to chemical hooks that selectively recognize and bind targeted proteins. Used in bioseparation applications, they can maximize the level of recovery, purity or cost improvements. Alternatively, the ligand can be designed to bind impurities such as undesirable proteins or toxins (i.e. biocontaminants) that must be removed from the final therapeutic product.

ProMetic's core technology has commercial applications in a wide range of areas, from proteomics to industrial biopharmaceutical manufacturing and from blood products safety to diagnostic and therapeutics.

ProMetic's business model is to accumulate multiple long-term annuity revenues through collaboration based on its core technology, while advancing its own therapeutic products toward commercialization.

Partners use ProMetic's core technology to enable or improve the manufacturing of their own therapeutics, both in terms of product yield and safety. In addition to improving the manufacturing processes of established marketed therapeutic products, ProMetic's technology is also applied to the development of second generation of recombinant therapeutic products.

While establishing a solid base to drive revenue growth, ProMetic is also leveraging its expertise in protein therapeutics and medicinal chemistry to accumulate an impressive pipeline of therapeutic products. ProMetic strives to develop drugs internally that target unmet medical needs where standard therapies are either in limited supply or

economically burdensome. This is particularly true for ProMetic's two lead compounds, recombinant Alpha 1-antitrypsin (rAAT) and PBI-1402.

CORE TECHNOLOGIES

Mimetic Ligand™ and “Intelligent Combinatorial Chemistry (ICC)®”

The drug discovery process has accelerated in recent years with the introduction of combinatorial chemistry, which allows millions of pharmacological agents to be screened in a relatively short time. ProMetic has applied this technology to the development of synthetic organic entities known as ligands that can be used in the separation and purification of biopharmaceutical products. Since the underlying mechanism is a very specific interaction between the naturally-occurring protein in blood or specific organs and the ligands, the ligands developed for purification purposes also have biomedical device applications and can be developed as distinct drugs. Over time, ProMetic has created its Intelligent Combinatorial Chemistry (ICC)®, which contains large quantities of Mimetic Ligands™ specific to certain classes of proteins such as monoclonal antibodies.

Particles Technology

Mimetic Ligands™ are attached to a support matrix such as agarose beads (PuraBead®) or fluorinated polymer. Therefore, each ligand, the binding chemistry and the bead are critical to the production of a final proprietary product, which is then incorporated into a bioseparation process or a particular medical device.

The Purabead® beads are produced from a ProMetic proprietary process. Agarose is a natural carbohydrate derived from agar-agar in seaweed and is widely used in the bioseparation and food industries. As such, agarose is a very well known and characterized raw material. The manufacturing process developed by ProMetic converts agarose into monodispersed beads to which the Mimetic Ligands™ are attached. The Fluorinated Polymers are also produced from a ProMetic proprietary process.

The choice of the base matrix will vary according to the specifications required by particular applications. ProMetic has developed and/or acquired methods to attach its ligands to matrices.

COMMERCIAL APPLICATIONS

Pursuant to its business plan, ProMetic leverages its platform technology by developing in-house “high value therapeutics” and medical applications and limits its risk exposure through partnerships with multinationals for product development, clinical trials and marketing.

By pursuing its business model, ProMetic also fosters growth by providing its enabling technology under license to pharmaceutical and biotech companies so as to enable them to develop proprietary products relying on ProMetic's technology.

Hence, ProMetic expects to generate revenues through the sale of its own therapeutics and through the licensing of its enabling technology to corporate strategic partners with long-term supply agreements and annuity revenue.

For further information and details on each project pursued and their status, please refer to pp. 4 to 12 of the Corporation's 2002 Annual Report.

COMPETITIVE CONDITIONS

ProMetic's competitive edge continues to be in the ability to apply its core technology to a wide range of products already on the market; in the ability of its technology to improve the manufacturing of these products in terms of product yield, safety or cost improvements; the ability to apply its core technology in many other areas such as drug discovery, proteomics, diagnostics, blood safety and establish a solid base to drive revenue growth; in leveraging its expertise in protein therapeutics and medicinal chemistry to develop and build on an impressive pipeline of therapeutic products that target unmet medical needs where standard therapies are either in limited supply or economically burdensome.

Competition in the biopharmaceutical sector is however extremely intense. ProMetic competes with companies that produce similar or identical biopharmaceutical products or that proposes different approaches to the separation or purification of proteins. Many of such companies have greater resources than ProMetic. Accordingly, no assurance can be given that products developed by these other companies or that their equivalent technology will not affect ProMetic's competitiveness.

AVAILABILITY AND SOURCES OF RAW MATERIALS

ProMetic depends on third parties for the sourcing of components for its various products. ProMetic believes that alternative sources of supply for its various raw material exist. However, any change by ProMetic in its supplier of components for its technology could have a significant impact on ProMetic's capacity to complete certain of its current research and development projects and, accordingly, would affect its projected commercial and financial growth. While other potential alternative suppliers of raw material have been identified or are in the process of being determined, they must first pass intensive validation tests to ensure their compliance with product specifications. No assurance can be given regarding the successful outcomes of such tests.

INTELLECTUAL PROPERTY RIGHTS

ProMetic's success depends in part on its ability to obtain patents, protect its trade secrets and operate without infringing third-party exclusive rights or without others infringing ProMetic's exclusive rights or those granted to it under license. ProMetic has filed patent applications in Canada, the United States and elsewhere in the world and is actively pursuing these matters. The patent position of biopharmaceutical firms is generally uncertain and involves complex legal, factual and scientific issues, several of which remain unresolved. The Corporation does not know whether any of ProMetic's pending patent applications will be granted or whether ProMetic will be able to develop other patentable proprietary products. Furthermore, ProMetic does not know whether its existing or future patents will provide a competitive advantage or afford protection against competitors with similar technology. Furthermore the Corporation cannot give any assurance that such patents will not be challenged successfully or circumvented by others using alternative technology or whether existing third-party patents will prevent ProMetic from marketing its products. In addition, competitors or potential competitors may independently develop products as effective as those of ProMetic or invent other products based on ProMetic's patented products.

Pharmaceutical and biopharmaceutical companies and research and development and academic institutions have filed patent applications for processes related to those of ProMetic of which may have an effect on the business of ProMetic. Some of these applications have been granted. Some of the processes and patents may conflict with the processes or patent applications of ProMetic, which could limit the scope of the patents that may be granted to ProMetic or even result in its patent applications being rejected.

If third-party licenses are required, there can be no assurance that ProMetic will be able to obtain such licenses, or if obtainable, that it would be available on reasonable terms. Furthermore there can be no assurance that ProMetic could develop or obtain alternative technologies related to third party patents that may inadvertently cover its products. Inability to obtain such licenses or alternative technologies could delay the market launch of certain ProMetic products, or even prevent ProMetic from developing, manufacturing or selling certain products. In addition, ProMetic could incur significant costs in defending itself in patent infringement proceedings initiated against it or in bringing infringement proceedings against others.

The Corporation cannot determine with any certainty if it has priority of invention in relation to a product or process covered by a patent application or if it was the first to file a patent application for any such invention. Further, in the event of patent litigation there can be no assurance that ProMetic's patents, if issued, would be held valid or enforceable by a court of competent jurisdiction or that a court would rule that the competitor's products or technologies constitute patent infringement.

Moreover, a significant part of ProMetic's technological know-how constitutes trade secrets. ProMetic, therefore, requires that its employees, consultants, advisers and collaborators sign confidentiality agreements. However, there can be no assurance that such agreements provide adequate protection in the event of unauthorized use or disclosure of ProMetic's trade secrets, know-how or other proprietary information.

RELIANCE ON COLLABORATIVE PARTNERS

ProMetic's strategy involves entering into various arrangements with corporate and academic partners, licensors, licensees and others for the research, development, clinical testing, manufacturing, marketing and commercialization of its core technology and therapeutic products. Under such agreements, ProMetic may receive additional funding, including milestone payments. However, there can be no assurance that it will be able to establish such partnerships on favourable terms, or that its current and future partnership arrangements will prove successful.

Should any of its collaborative partners be unsuccessful in developing or commercializing a ProMetic product or its core technology to which the partner has rights, or one of the partner's products to which ProMetic has rights, ProMetic's business could be adversely affected. Furthermore, while the Corporation believes that the current and future corporate partners have sufficient financial motivation to maintain their funding, there can be no assurance that these partnership arrangements will continue or that they will result in successful commercialization of ProMetic products. Should one of ProMetic's collaborators terminate its funding of a particular program, this could delay or interrupt the development or commercialization of the products resulting from such program. Moreover, there can be no assurance that the partners will not pursue other technologies or develop alternative products, either on their own or in collaboration with

others, including competitors of ProMetic, as a means for developing products that treat the same diseases as those targeted by ProMetic's various programs.

PRODUCT DEVELOPMENT

ProMetic currently has many collaboration agreements based on its core technology for the improvement of established and marketed therapies by improving manufacturing process yield and purity, and by developing recombinant versions of such established proteins (e.g. rAAT). ProMetic also leverage its expertise in protein therapeutics and medicinal chemistry and has accumulated an impressive pipeline of therapeutic products for which the development is conducted in-house. Two products addressing inflammatory disorders and two products in the cancer area are currently being pursued as a first tranche of products. ProMetic believes it is important to maintain a balance between in-house product development products and partnered products. Developing products internally provides greater control over the pace of development and the potential for higher commercial returns. Furthermore, it allows ProMetic to develop the necessary skill sets as it drives toward its goal of becoming a fully integrated specialty pharmaceutical company. Pursuing the commercialization phase in partnership with other firms is also important because it provides continuous external validation of ProMetic's technology and possibilities of short-term revenue from fees collected at the initiation of the partnership and milestones payments.

RESEARCH AND DEVELOPMENT

ProMetic's policy for research and development is to have readily available funds required to conduct its activities. ProMetic's strategy is to finance research activities through the formation of strategic alliances with pharmaceutical and biopharmaceutical companies for the improvement of their manufacturing capacity or process for their therapeutics and the development of second generation of recombinant therapeutic products, financings, and grants or tax credits for such purposes. In addition, activities are financed through. During the course of the financial year ended December 31, 2002, ProMetic invested approximately \$10 Million in research and development. Revenues were also generated via these collaboration agreements, \$ 2.5 Million during the financial year ended on December 31, 2002.

ENVIRONMENT

ProMetic produces a certain amount of chemical waste in its R&D and manufacturing activities, which is removed in accordance with the applicable environmental protection standards by companies that specialize in hazardous waste management. ProMetic research laboratories generate radioactive waste that is also removed by companies that specialize in hazardous waste management, in accordance with strict internal procedures and in accordance with the applicable regulatory requirements. Compliance with environmental protection requirements does not have a significant effect on ProMetic's capital expenditures or on its competitive position.

HUMAN RESOURCES

ProMetic has highly qualified employees with specialized backgrounds in the biological and chemical sciences. This is leveraged by the fact that several hundreds scientists and managers within multinationals work on joint projects with ProMetic. This enables ProMetic to gain access to this workforce and knowledge base without having to carry it

on its payroll. ProMetic has also recruited experienced professionals in the area of business development, finance and accounting. The total number of employees is 99 on a consolidated basis.

INTERNATIONAL BUSINESS

Most of ProMetic's bioseparation and medical business is conducted on international markets and the Corporation expects this to continue. The majority of ProMetic's expenses are incurred in pounds Sterling. The sale of ProMetic's products on international markets is subject to the risks that are normally associated therewith, such as government regulation, import and export licence requirements, risks related to tariffs or trade barriers, and political and economic instability. While such risks have not to date had any material adverse effect on ProMetic, there can be no assurance that this will not occur in the future. Currency-related risks primarily concern appreciation of the Canadian dollar against a particular foreign currency. There can be no assurance that the Canadian dollar will not increase in relation to currencies, which could reduce ProMetic's returns on sales of its products expressed in Canadian dollars. Furthermore, there can be no assurance given against major currency fluctuations, which could create sizeable discrepancies in the prices of products in various countries requiring ProMetic to consider reducing its prices in certain currencies in order to balance the relative cost of its products. The Corporation neither holds nor issues financial instruments for commercial or hedging purposes.

Item 4 – Selected Consolidated Financial Information

4.1 Annual Information

	12 month Period Dec. 31, 2002	12 Month Period Dec. 31, 2001	12 Month Period Dec. 31, 2000
Operating Revenues	\$2,511,663	\$2,500,795	\$2,079,339
Financial (Revenues) Expenses, Net	(\$288,716)	(\$62,633)	\$101,086
Net Loss	\$14,111,303	\$8,415,085	\$5,167,640
Net Loss Per Share	\$0.19	\$0.14	\$0.10
Total Assets	\$39,457,215	\$24,311,995	\$14,187,437
Long-term Debt	\$582,404	-	-

4.2 Dividends

To date, the Corporation has not paid any dividends in respect of its outstanding shares nor in respect of any class of shares of its share capital, and it does not anticipate paying dividends in the foreseeable future. At the present time, the policy of the Board of Directors of the Corporation is to reinvest all available funds in operating activities. The Board of Directors periodically reviews this policy.

Item 5 – Management’s Discussion and Analysis of Financial Position and Operating Results

Management’s Discussion and Analysis of Financial Condition and Results of Operations included on pp. 13 to 16 of the Corporation’s 2002 Annual Report for the fiscal year ended December 31, 2002 is incorporated herein by reference.

Item 6 - Market for Securities

The Corporation’s Subordinate Voting Shares are listed on the Toronto Stock Exchange under the symbol “PLI”.

Item 7 - Directors and Officers

DIRECTORS

The following table sets forth the names and the municipality of residence of all the directors, their position with the Corporation, their present principal occupation and the year in which they became a director of the Corporation.

(The present term of each director will expire immediately prior to the election of directors at the annual shareholder’s meeting to be held on May 28, 2003).

Directors

Name and Municipality of Residence	Position with the Corporation	Director Since	Principal occupation
Pierre Laurin Montreal, Quebec	Director and Chairman	1994	Chairman, President and Chief Executive Officer, ProMetic
Roger Garon ⁽³⁾ Montreal, Quebec	Director	1995	Chairman, Multivet Ltd (a Veterinary Products Company) and Trustee of the Noranda Income Fund
Barry Gibson Naples, Florida, USA	Director	1994	Consultant
Claude Lemire ⁽¹⁾ Brossard, Quebec	Director	1997	Consultant
Roger A. Perrault ⁽²⁾⁽³⁾ Ottawa, Ontario	Director	1998	President, R.A. Perrault Consultants Inc.
Hans W. Schmid ⁽³⁾ Zug, Switzerland	Director	1998	Chairman, HPC Healthcare & Pharma Consulting AG, ASAT AG Applied Science and Technology and ASAT AG Biotec
Sadok Besrou ⁽¹⁾⁽²⁾ Westmount, Quebec	Director	2000	President, Placements Sadobex Inc.
Robert Lacroix ⁽¹⁾⁽²⁾ St-Bruno, Quebec	Director	2000	Senior Vice-President, CTI Capital Inc.

Name and Municipality of Residence	Position with the Corporation	Director Since	Principal occupation
John Bienenstock Toronto, Ontario	Director	2000	University Professor McMaster University Director, Brain-Body Institute St. Joseph's Healthcare Hamilton

- (1) Member of the Audit Committee.
- (2) Member of the Corporate Governance Committee.
- (3) Member of the Compensation Committee.

During the last five (5) years, all of the above directors have held the principal occupation shown above.

OFFICERS

The following table sets forth the name of each ProMetic officer, his or her municipality of residence, his or her position with ProMetic, the principal operating subsidiaries in which each officer currently holds office as of the date hereof, the year he or she took up his or her position and the positions held for the last five years.

Officers

Name and Municipality of Residence	Position	Since
Pierre Laurin Montreal, Quebec	Chairman of the Board, President and Chief Executive Officer, ProMetic	1994
André Bédard ⁽¹⁾ Rosemère, Quebec	Chief Operating Officer, ProMetic	1999
Geneviève Poulin ⁽¹⁾ Montreal, Quebec	Vice-President, Finance and Chief Financial Officer, ProMetic	2003
Steven J. Burton Cambridge, England	Vice-President Research and Development, ProMetic BioSciences (UK)	1998
Peter Bonnett Silver Spring, Maryland, U.S.A.	Vice-President, North American Operations, ProMetic BioSciences (U.S.A.)	1994
Michelle Laflamme Montreal, Quebec	General Counsel and Secretary, ProMetic	1998

During the last five (5) years, all of the above officers have held the position shown above except for (i) André Bédard who was Executive Vice-President, Finance and Chief Executive Officer of ProMetic from September 1999 to March 31, 2003 and prior to was President of Conseils Vision A. Bédard Inc., and (ii) Geneviève Poulin who was Health Care and Biotechnology Analyst at the Financial National Bank from October 2001 to

March 2003 and at the Laurentian Bank from December 1999 to October 2001 and prior to with Sofinov of the group of *Caisse de dépôt et placement du Québec* from September 1998 to December 1999.

Security Holdings

As of March 31, 2003, the number and percentage of securities of Subordinate Voting Shares and Multiple Voting Shares of the Corporation or its subsidiaries beneficially owned directly or indirectly, or over which control or direction is exercised, by all directors and executive officers of the Corporation as a group is:

	Number	%
Subordinate Voting Shares	1,978,546	2.67%
Multiple Voting Shares	13,026,375	100%

The information as to the number of Subordinate Voting Shares and Multiple Voting Shares beneficially owned or over which control is exercised, not being within the knowledge of the Corporation, has been provided by each director and executive officer.

Item 8 - Additional Information

The Corporation will provide to any person, upon written request made to the Secretary of the Corporation (8168 Montview Road, Montreal, Quebec H4P 2L7, telephone: (514) 341-2115):

- a) when the securities of the Corporation are in the course of a distribution pursuant to a short form prospectus or a preliminary short form prospectus has been filed in respect of a distribution of its securities.
 - i) one copy of the AIF of the Corporation, together with one copy of any document, or the pertinent pages of any document, incorporated by reference in the AIF;
 - ii) one copy of the comparative financial statements of the Corporation for its most recent completed financial year for which financial statements have been filed together with the accompanying report of the auditor and one copy of the most recent interim financial statements of the Corporation that have been filed, if any, subsequent to the financial statements for the Corporation most recently completed financial year;
 - iii) one copy of the information circular of the Corporation in respect of its most recent annual meeting of shareholders that involved the election of directors or one copy of any annual filing prepared in lieu of that information circular, as appropriate; and
 - iv) one copy of any other documents that are incorporated by reference into the preliminary short form prospectus or the short form prospectus and are not required to be provided under i) to iii) above, or

(b) at any other time, one copy of any other documents referred to in (a) i), ii) and iii) above, provided the Corporation may require the payment of a reasonable charge if the request is made by a person who is not a security holder of the Corporation. The public documents of the Corporation can also be accessed via Internet at the SEDAR Website (www.sedar.com) or the Corporation's Website (www.prometic.com).

Additional information including directors' and officers' remuneration and indebtedness, principal holders of the Corporation's securities, options to purchase securities and interest of insiders in material transactions, where applicable, is contained in the Corporation's Management Proxy Circular for its most recent annual meeting of shareholders that involved the election of directors, and additional financial information is provided in the Corporation's comparative financial statements for its most recently completed financial year.

* * *